Immunomodulatory Agents in Follicular Lymphoma.
Antineoplastic Agents
/ pharmacology
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Immunologic Factors
/ pharmacology
Immunological Synapses
/ drug effects
Immunomodulation
/ drug effects
Lenalidomide
/ pharmacology
Lymphoma, Follicular
/ diagnosis
Molecular Targeted Therapy
Treatment Outcome
Tumor Microenvironment
/ drug effects
Chemo-free approaches
Follicular lymphoma
Immunomodulatory agents
Monoclonal antibodies
Tumor immune microenvironment
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
9
2
2021
Statut:
ppublish
Résumé
New treatment strategies in follicular lymphoma (FL) are driven by a deeper understanding of microenvironmental cues supporting lymphomagenesis, chemoresistance, and immuno-escape. These immune-mediated signaling pathways contribute to initial learnings and clinical successes with lenalidomide, the first, oral, non-chemotherapeutic immunomodulatory drug, combined with anti-CD20 antibodies. This combination of lenalidomide with rituximab showed similar efficacy to chemoimmunotherapy (CIT) in first-line patients requiring therapy, and is approved in relapsed/refractory FL. We review the biology supporting the rationale for adequate inhibitory receptor/ligand pathways targeting the tissue immune microenvironment of FL cells, and potential immunomodulating combinations to replace CIT in the near future.
Identifiants
pubmed: 32586576
pii: S0889-8588(20)30032-0
doi: 10.1016/j.hoc.2020.02.007
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Immunologic Factors
0
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
715-726Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure F. Morschhauser: Consultancy (F. Hoffmann-La Roche), honoraria for scientific lectures (Celgene, F. Hoffmann-La Roche, and Janssen), Advisory committee (Bayer, Bristol-Myers Squibb, Celgene, Epizyme, F. Hoffmann-La Roche, and Gilead). L. Ysebaert: Consultancy (AbbVie, F. Hoffmann-La Roche, Gilead, and Janssen), honoraria for scientific lectures (AbbVie, Astra-Zeneca, Celgene, F. Hoffmann-La Roche, Gilead, Janssen).